Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared on X:
“Another trial unfortunately negative for our patients with pancreas cancer.
As mentioned, innovation is needed.
The PanCAN is a great platform to study novel drugs. While mechanistically, Pamrevlumab was of value to study, it didn’t improve survival.”
